Cargando…

One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy

This study investigated one-year outcomes of treatment with one session of intravitreal recombinant tissue plasminogen activator, ranibizumab, and gas injections for submacular hemorrhage secondary to polypoidal choroidal vasculopathy (PCV). An extended study of a previous prospective trial of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitagawa, Yorihisa, Shimada, Hiroyuki, Mori, Ryusaburo, Tanaka, Koji, Wakatsuki, Yu, Onoe, Hajime, Kaneko, Hiroyuki, Machida, Yumiko, Nakashizuka, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032067/
https://www.ncbi.nlm.nih.gov/pubmed/35456268
http://dx.doi.org/10.3390/jcm11082175
_version_ 1784692549115445248
author Kitagawa, Yorihisa
Shimada, Hiroyuki
Mori, Ryusaburo
Tanaka, Koji
Wakatsuki, Yu
Onoe, Hajime
Kaneko, Hiroyuki
Machida, Yumiko
Nakashizuka, Hiroyuki
author_facet Kitagawa, Yorihisa
Shimada, Hiroyuki
Mori, Ryusaburo
Tanaka, Koji
Wakatsuki, Yu
Onoe, Hajime
Kaneko, Hiroyuki
Machida, Yumiko
Nakashizuka, Hiroyuki
author_sort Kitagawa, Yorihisa
collection PubMed
description This study investigated one-year outcomes of treatment with one session of intravitreal recombinant tissue plasminogen activator, ranibizumab, and gas injections for submacular hemorrhage secondary to polypoidal choroidal vasculopathy (PCV). An extended study of a previous prospective trial of this treatment modality in PCV patients was conducted in 64 patients (64 eyes). Early Treatment Diabetic Retinopathy Study (ETDRS) score, central retinal thickness (CRT), and central pigment epithelial detachment thickness (CPEDT) before and 1, 3, and 12 months after treatment were analyzed. Mean ETDRS score increased from 58 at baseline to 64 letters (p = 0.0122), CRT decreased from 543 to 192 μm (p < 0.0001), and CPEDT decreased from 161 to 103 μm (p = 0.0668) at 3 months and were maintained until 12 months. Complications requiring reoperation occurred within one month in four eyes. Recurrence was observed in 46 eyes (72%), and 1.6 ± 1.5 (0–7) intravitreal aflibercept injections were given pro re nata. Univariate and multivariate analyses identified CPEDT as the pre- and post-treatment factor affecting 12-month ETDRS score (p < 0.0001). Improved visual acuity stabilized 3 months after treatment. Although 72% of patients experienced recurrence, an average of 1.6 aflibercept injections/patient maintained visual acuity up to 12 months. CPEDT was the most important factor associated with visual outcome.
format Online
Article
Text
id pubmed-9032067
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90320672022-04-23 One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy Kitagawa, Yorihisa Shimada, Hiroyuki Mori, Ryusaburo Tanaka, Koji Wakatsuki, Yu Onoe, Hajime Kaneko, Hiroyuki Machida, Yumiko Nakashizuka, Hiroyuki J Clin Med Article This study investigated one-year outcomes of treatment with one session of intravitreal recombinant tissue plasminogen activator, ranibizumab, and gas injections for submacular hemorrhage secondary to polypoidal choroidal vasculopathy (PCV). An extended study of a previous prospective trial of this treatment modality in PCV patients was conducted in 64 patients (64 eyes). Early Treatment Diabetic Retinopathy Study (ETDRS) score, central retinal thickness (CRT), and central pigment epithelial detachment thickness (CPEDT) before and 1, 3, and 12 months after treatment were analyzed. Mean ETDRS score increased from 58 at baseline to 64 letters (p = 0.0122), CRT decreased from 543 to 192 μm (p < 0.0001), and CPEDT decreased from 161 to 103 μm (p = 0.0668) at 3 months and were maintained until 12 months. Complications requiring reoperation occurred within one month in four eyes. Recurrence was observed in 46 eyes (72%), and 1.6 ± 1.5 (0–7) intravitreal aflibercept injections were given pro re nata. Univariate and multivariate analyses identified CPEDT as the pre- and post-treatment factor affecting 12-month ETDRS score (p < 0.0001). Improved visual acuity stabilized 3 months after treatment. Although 72% of patients experienced recurrence, an average of 1.6 aflibercept injections/patient maintained visual acuity up to 12 months. CPEDT was the most important factor associated with visual outcome. MDPI 2022-04-13 /pmc/articles/PMC9032067/ /pubmed/35456268 http://dx.doi.org/10.3390/jcm11082175 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kitagawa, Yorihisa
Shimada, Hiroyuki
Mori, Ryusaburo
Tanaka, Koji
Wakatsuki, Yu
Onoe, Hajime
Kaneko, Hiroyuki
Machida, Yumiko
Nakashizuka, Hiroyuki
One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy
title One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy
title_full One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy
title_fullStr One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy
title_full_unstemmed One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy
title_short One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy
title_sort one-year outcome of intravitreal tissue plasminogen activator, ranibizumab, and gas injections for submacular hemorrhage in polypoidal choroidal vasculopathy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032067/
https://www.ncbi.nlm.nih.gov/pubmed/35456268
http://dx.doi.org/10.3390/jcm11082175
work_keys_str_mv AT kitagawayorihisa oneyearoutcomeofintravitrealtissueplasminogenactivatorranibizumabandgasinjectionsforsubmacularhemorrhageinpolypoidalchoroidalvasculopathy
AT shimadahiroyuki oneyearoutcomeofintravitrealtissueplasminogenactivatorranibizumabandgasinjectionsforsubmacularhemorrhageinpolypoidalchoroidalvasculopathy
AT moriryusaburo oneyearoutcomeofintravitrealtissueplasminogenactivatorranibizumabandgasinjectionsforsubmacularhemorrhageinpolypoidalchoroidalvasculopathy
AT tanakakoji oneyearoutcomeofintravitrealtissueplasminogenactivatorranibizumabandgasinjectionsforsubmacularhemorrhageinpolypoidalchoroidalvasculopathy
AT wakatsukiyu oneyearoutcomeofintravitrealtissueplasminogenactivatorranibizumabandgasinjectionsforsubmacularhemorrhageinpolypoidalchoroidalvasculopathy
AT onoehajime oneyearoutcomeofintravitrealtissueplasminogenactivatorranibizumabandgasinjectionsforsubmacularhemorrhageinpolypoidalchoroidalvasculopathy
AT kanekohiroyuki oneyearoutcomeofintravitrealtissueplasminogenactivatorranibizumabandgasinjectionsforsubmacularhemorrhageinpolypoidalchoroidalvasculopathy
AT machidayumiko oneyearoutcomeofintravitrealtissueplasminogenactivatorranibizumabandgasinjectionsforsubmacularhemorrhageinpolypoidalchoroidalvasculopathy
AT nakashizukahiroyuki oneyearoutcomeofintravitrealtissueplasminogenactivatorranibizumabandgasinjectionsforsubmacularhemorrhageinpolypoidalchoroidalvasculopathy